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Simple Summary: The influence of nerves on different types of cancers, including colorectal cancer,
is increasingly recognized. The intestines are highly innervated, both from outside the intestines
(extrinsic innervation) and by a nervous system of their own; the enteric nervous system (intrinsic
innervation). Nerves and cancer cells have been described to communicate with each other, although
the exact mechanism in colorectal cancer is not yet explored. Nerves can enhance cancer progression
by secreting signaling molecules, and cancer cells are capable of stimulating nerve growth. This
review summarizes the innervation of the intestines and current knowledge on the role of the nervous
system in colorectal cancer. Additionally, the therapeutic potential of these new insights is discussed.
Abstract: The role of the nervous system as a contributor in the tumor microenvironment has been
recognized in different cancer types, including colorectal cancer (CRC). The gastrointestinal tract is a
highly innervated organ system, which is not only innervated by the autonomic nervous system, but
also contains an extensive nervous system of its own; the enteric nervous system (ENS). The ENS is
important for gut function and homeostasis by regulating processes such as fluid absorption, blood
flow, and gut motility. Dysfunction of the ENS has been linked with multiple gastrointestinal diseases,
such as Hirschsprung disease and inflammatory bowel disease, and even with neurodegenerative
disorders. How the extrinsic and intrinsic innervation of the gut contributes to CRC is not fully
understood, although a mutual relationship between cancer cells and nerves has been described.
Nerves enhance cancer progression through the secretion of neurotransmitters and neuropeptides,
and cancer cells are capable of stimulating nerve growth. This review summarizes and discusses the
nervous system innervation of the gastrointestinal tract and how it can influence carcinogenesis, and
vice versa. Lastly, the therapeutic potential of these novel insights is discussed.
Keywords: tumor microenvironment; colorectal cancer; neurons; glia; nerves; innervation; enteric
nervous system; peripheral nervous system
1. Introduction
Cancer is one of the most complex diseases due to a phenomenon called tumor het-
erogeneity, the molecular diversity between and within tumors [1]. This complicates the
search for and applicability of treatments. A major contribution to tumor heterogeneity
comes from the cells and components surrounding the tumor cells, the tumor microenvi-
ronment (TME). Classically, the TME is considered to comprise fibroblasts, myofibroblasts,
immune cells, adipose cells, neuroendocrine cells, vasculature, the lymphatic system, and
extracellular matrix components [2]. Only in the last decade, the role of another component
of the TME, namely the nervous system, has gained attention in different tumor types
including gastric [3], prostate [4,5], breast [6], pancreatic [7] and colorectal cancer (CRC) [8];
which has been reviewed by Zahalka and Frenette [9].
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Although the central nervous system (CNS) is a relatively secluded part of the nervous
system, protected by the blood–brain barrier, the peripheral nervous system (PNS) emerges
as ganglia that reside in relative proximity to the organs they innervate. Neuronal cell
bodies of the PNS, and especially neural endings, are situated within or adjacent to the
TME, which can be influenced by the tumor and vice versa [4,10,11].
In CRC, the mechanisms by which neurons influence carcinogenesis are largely un-
known. This is striking, because the gastrointestinal (GI) tract is a highly innervated organ
system with major connections to the CNS, but also contains a nervous system of its own:
the enteric nervous system (ENS). The ENS is composed of neurons and glia structured in
ganglia in the gut wall, which influence gut homeostasis, by regulating digestive functions
such as secretion and absorption, local blood flow and gut motility [12]. The importance
of enteric neurons in CRC was reviewed by Rademakers et al. in 2017 [13], focusing on
the link between the ENS, inflammation, and CRC, as well as perineural invasion, and
neurotransmitters involved in CRC. Limited new data have become available regarding the
role of nerves and neurons in CRC. Furthermore, enteric glial cells (EGCs) are becoming
more and more appreciated for their role in the above-mentioned functions of the ENS and
their influence on enteric neuron activity and function [14]. A role for EGCs in CRC has
also been proposed.
In this review, we provide an overview of the extrinsic and intrinsic nervous system
innervation in the GI tract, summarize current literature about the role of neuronal in-
nervation and EGCs in CRC, and highlight the latest research and therapeutic potential
involving the nervous system and CRC.
2. Innervation of the Gastrointestinal Tract
Mammalian gut function largely depends on both extrinsic and intrinsic neural path-
ways innervating the GI tract. The extrinsic innervation, for which the neuronal cell bodies
are located outside the gut, comprises both sympathetic and parasympathetic projections,
as well as visceral afferents. The ENS, which is embedded in the gut wall, supplies the
intrinsic innervation [15,16] (Figure 1).
2.1. Extrinsic Innervation: The Sympathetic and Parasympathetic Nervous System
The neuronal cell bodies of extrinsic neurons innervating the gut are located in the
brainstem, prevertebral ganglia and peripheral afferent ganglia (Figure 1). After coloniza-
tion of the gut by ENS precursors, fibers from extrinsic sensory and visceromotor neurons
project to the gut. These originate from vagal, dorsal root, sympathetic, and pelvic ganglia.
Sympathetic fibers typically travel along blood vessels, while parasympathetic fibers enter
the gut via the vagus nerve or spinal cord. During embryogenesis, vagal innervation is
directed by chemoattractants and chemorepellents secreted by the developing epithelium,
mesenchyme, and enteric neurons, but how spinal afferents innervate the gut during
development is still largely unknown [17].
Sympathetic nerves have their cell bodies located in the sympathetic chain next to the
spinal cord (the so-called paravertebral ganglia) and in prevertebral ganglia, which are
located more closely to the GI tract (Figure 1). Sympathetic activation leads to the release
of noradrenaline along with a release of other neurotransmitters, and generally delays
intestinal transit and secretion via the inhibition of enteric (secreto) motor neurons, direct
inhibition of smooth muscle cells contraction, and secretory actions, by inducing intestinal
vasoconstriction. Sympathetic activity also causes the contraction of sphincters [18].
In contrast to the inhibitory action of sympathetic innervation, parasympathetic nerves
have inhibitory and excitatory control over gastrointestinal motility, typically by releas-
ing acetylcholine [19]. Parasympathetic nerve cell bodies are located in the brainstem
and project to the stomach, small intestine, and proximal colon through the vagus nerve
(Figure 1). Vagal input in the intestines occurs through the connection of a vagal fiber to
multiple enteric neurons [20]. In this way, the vagus nerve can modulate ENS activity
in a general manner. Sacral preganglionic neurons in the spinal cord and in the sacral
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parasympathetic nucleus control parasympathetic activity in the distal colon via commu-
nication with enteric neurons either directly or indirectly [19]. Both the vagus and pelvic
nerve contain efferent (motor) and afferent (sensory) nerve fibers. These afferent nerves
transfer sensory information from the GI tract to the CNS. Vagal afferent nerves have cell
bodies located in the nodose and jugular ganglia, and project from there to the brain. Other
afferent nerves enter the spinal cord (and thus the CNS) directly and are referred to as
spinal afferents [21]. They have nerve endings in the mucosa, enteric ganglia, or in the
muscle layer and are important for the control of gut function and GI sensation, including
pain and satiety [22].
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Figure 1. Schematic of the extrinsic and intrinsic innervation of the gastrointestinal tract. Extrinsic
innervation comprises both the sympathetic (yellow) and the parasympathetic (blue) nervous system.
The sympathetic nervous system has cell bodies located in paravertebral ganglia (next to the spinal
cord) and prevertebral ganglia (close to the gastrointestinal tract). The parasympathetic nervous
system projects to the stomach, small intestine, colon, and rectum via the vagus nerve and the
pelvic nerve. Intrinsic gastrointestinal innervation is provided by the enteric nervous system, which
comprises multiple neuronal types clustered within the myenteric plexus (MP) and submucosal
plexus (SMP). The major neuronal types in the enteric nervous system are intrinsic primary afferent
neurons (sensory neurons with Dogiel type II morphology that project to the mucosa, black), de-
scending (purple) and ascending (green) interneurons, secretomotor and vasodilatator neurons (red),
excitatory (blue) and inhibitory (orange) motorneurons, and intestinofugal neurons (pink). SMP,
submucosal plexus; CM, circular muscle; MP, myenteric plexus; LM, longitudinal muscle. (Created
with Biorender.com).
2.2. Intrinsic Innervation: The Enteric Nervous System
In mammals, such as humans and mice, intrinsic neuronal innervation of the gut
is initiated during embryogenesis with vagal neural crest cells invading the foregut [23].
These enteric neural crest cells migrate in a rostral-to-caudal direction along the developing
intestine. In addition, a relatively small group of ENS precursors originating from the
sacral neural crest contributes to the colonization of the hindgut [23]. Successful ENS
development requires extensive proliferation and differentiation into balanced numbers of
functional enteric neuron and glial subtypes [17,24].
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Mature enteric neurons and part of the EGCs are clustered in the myenteric and
submucosal plexus, which are described as mesh-like structures embedded in the GI
wall. The myenteric plexus ranges along the entire length of the GI tract, whereas the
submucosal plexus is only located in the small and large intestine [16]. The ENS con-
tains diverse neuronal and glial subtypes with varying transcriptomic, phenotypic, and
functional properties [25–28].
The major neuronal types are motor neurons innervating the smooth muscle layers,
vasodilatator neurons, secretomotor neurons, intrinsic primary afferent neurons (IPANs;
intrinsic sensory neurons with Dogiel type II morphology that innervate the gut mucosa),
interneurons, and intestinofugal neurons (Figure 1), which can be subdivided in different
subpopulations as described in detail elsewhere [25,29,30].
EGCs can also be divided into multiple subtypes, mostly based on their location and
morphology [26,31–34]. Besides being present in the myenteric and submucosal plexus,
they can, contrary to enteric neurons, also be found in the lamina propria and muscle layers
of the gut.
Through the interplay between enteric neurons and glia, this intrinsic nervous system
can control many gastrointestinal functions autonomously. An important experiment,
performed in 1755, showed that an excised intestine, without any connection to the va-
gus nerve or the CNS, still exhibits peristaltic contractions [35]. Therefore, the ENS is
sometimes also referred to as “the second brain” or “the brain of the gut”. Although the
ENS is indispensable for GI function, input from the CNS is still important. There is great
connectivity between the ENS and CNS, and together they integrate signals to control
contractile bowel activity and secretion [16].
3. Nervous System Innervation in Colorectal Cancer
3.1. Neurons and Colorectal Cancer
Even though there is a booming interest in the role of neurons in cancer, knowledge on
the role of the neural systems innervating the gut in CRC is still limited. A passive role for
neurons in CRC and other cancer types has been recognized for several years in the context
of perineural invasion (PNI) [36]. In this process, tumor cells use the nerve fibers as leading
strands to migrate to other sites, which is linked to rapid tumor growth and metastasis [36].
In CRC, PNI was characterized as a prognostic marker for the aggressiveness of cancer
and for survival rates [37,38]. PNI is correlated with poorly differentiated and high-grade
colorectal tumors. Furthermore, PNI is associated with a reduced disease-free survival and
can serve as an independent prognostic marker for patient outcomes [38]. Rectal cancers
had a higher incidence of PNI, which correlates with their higher aggressiveness and poorer
overall survival rates compared to colon cancer. It is thought that the higher incidence of
PNI in the rectum is related to its denser extrinsic innervation compared to the colon [37,38].
PNI, however, is believed to arise via extrinsic nerve bundles from the PNS [39]; a physical
interaction between enteric neurons and CRC cells has been described. Enteric neurons
express N-cadherin and L1CAM, which were identified as important molecules for the
adhesion and migration of CRC cells [40]. However, deletion of these molecules did not
completely abrogate PNI, suggesting that other (unknown) molecules must be involved
as well.
Active communication between cancer and neuronal cells has been described for
different cancer types [9,41], identifying several ways of neuron–cancer signaling. By
experimentally altering neuronal signaling, it has been shown that nerves can influence
carcinogenesis. Tumor growth and cancer progression were enhanced by increasing ac-
tivation of sympathetic nerves in an animal model of breast cancer [42], while reducing
parasympathetic activity in the stomach inhibited gastric tumorigenesis [3]. In a genetic
mouse model of intestinal cancer (ApcMin/+ model), vagotomy decreased the tumor area, in-
dicating that extrinsic innervation from the vagus nerve could promote carcinogenesis [43].
In contrast, surgical sympathetic denervation at the level of the mesenteric artery did not
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inhibit tumor growth in the same study, which suggests that the mode of action of specific
nerves rather than neuronal activity per se affects carcinogenesis.
Furthermore, cancer cells can signal to neuronal cells as well. They aim to guide
innervation by expressing chemoattractant/-repellant and axon guidance molecules, as
observed in prostate [44] and pancreatic cancer [45]. Head and neck cancer cells release
vesicles (exosomes) containing EphrinB1 that can induce neurite outgrowth, and blocking
of exosome release attenuates tumor innervation in vivo [46]. In addition, Amit et al.
showed that head and neck cancer cells, mutant for p53, secrete the miRNA miR-43a within
vesicles, which drives the reprogramming of cancer-associated sensory nerves to become
adrenergic, similar to sympathetic neurons [47]. Together, this indicates that tumors are
able to induce their own innervation.
Besides this unidirectional communication, specific crosstalk has also been described
between cancer and neuronal cells, whereby nerves promote cancer development and
cancer cells induce tumor innervation in a feedforward loop [48,49]. In pancreatic cancer,
adrenergic signaling to tumor cells induces nerve growth factor (NGF) and brain-derived
neurotrophic factor (BDNF) release by tumor cells, resulting in increased nerve density
in the tumor area. This in turn results in increased adrenergic signaling, leading to accu-
mulation of noradrenaline and enhanced tumor growth [48]. In gastric cancer, cholinergic
nerves and Tuft cells affect tumorigenesis by releasing acetylcholine. This stimulates
the expression of NGF from epithelial cells, which in turn increases nerve and Tuft cell
density, thereby further enhancing acetylcholine release and neuronal innervation [49].
Interestingly, Hayakawa et al. also described an upregulation of NGF mRNA in murine
CRC tissue. Moreover, overexpression of NGF in the colon epithelium, using a Villin-Cre:
R26-NGF mouse line, resulted in the development of more and larger rectal tumors upon
chemical (AOM/DSS) tumor induction, indicating that a similar process could take place
in CRC [49].
So far, no specific bi-directional communication between neurons and cancer cells has
been described for CRC. However, there are multiple studies depicting a role for neurotrans-
mitters and neuropeptides in CRC, as previously summarized [13]. Since then, new studies
have confirmed the roles of some of these signaling molecules, including Substance P and
neurotensin as tumor-promoting signals, [50–52], somatostatin as a tumor-suppressing
signal [53], and galanin as a potential biomarker for CRC in sera and tissue [54,55]. More-
over, new functions for some of the described neuropeptides have been elucidated. It
was already established that neuropeptide Y (NPY) is produced by enteric neurons [56]
and functions in the regulation of inflammation in the gut [57], but its role in CRC was
largely unknown. Currently a tumor-promoting role for NPY is suggested, based on
observations that NPY-deficient mice displayed reduced inflammation, polyp size, and
polyp number in an inflammation model (DSS), and that NPY stimulates proliferation
and reduces apoptosis of tumor cells in vitro [58]. Studies have shown that serotonin
prevents DNA damage in the colon and thereby protects against early tumorigenesis [59],
and that gamma-aminobutyric acid (GABA) inhibits proliferation and increases sensitiv-
ity to chemotherapy in CRC cells [60]. Importantly, these signaling molecules can also
have tumor-promoting properties depending on the receptor to which they bind and the
pathways they consequentially activate or suppress [13].
Given that many neurotransmitters and neuropeptides have multiple receptors as
potential binding partners, it is important to profile the expression of different receptor
variants in CRC and to assess the effect of receptor activation on CRC progression. Fur-
thermore, the effect of neurotransmitters and neuropeptides on tumor growth could be
concentration dependent. This was shown for serotonin, where high doses exerted a
mitogenic effect, but low doses reduced growth by limiting the blood flow towards the
tumor [61]. Thus, this argues the importance of studying the concentration-dependent
effect of other neurotransmitters in the future. It is also noteworthy that some of these
signaling molecules are not solely secreted by (enteric) neurons, but can also be produced
by other cells, as well as by gut microbiota [62–65]. Thus, care has to be taken when
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concluding about the role of neurons in CRC based on neurotransmitter or neuropeptide
studies. An overview of the different tumor types, signaling factors, and their (presumed)
effect on tumor growth is given in Table 1.
While these modes of communication mostly involve paracrine signaling, exciting
new findings, for instance in glioma, show that specific synaptic connections between
neurons and cancer cells can be established as well [66,67]. Here, the neurons surrounding
the tumor secrete neuroligin-3, which promotes the formation of neuron–glioma synapses
with a specific type of glutamate receptors, AMPA-receptors, on the glioma cells [66,67]. Ac-
tivation of these neurons promotes cancer growth through glutamate release by promoting
proliferation and invasion of the glioma cells. Moreover, activation of AMPA-receptors on
glioma cells stimulates the release of glutamate from the glioma cells themselves, thereby
activating AMPA-receptors in an autocrine fashion and further activating neurons. Al-
though there is currently no evidence for functional synapses between neurons and CRC
cells, enteric neurons have been observed in close proximity to tumor cells [40]. Moreover,
increased glutamate receptor expression has been associated with CRC [68]. In the future,
it would be interesting to study whether synaptic-like connections are formed between
neurons and CRC cells.
Table 1. The effect of the presence and activity of various nerves and neurotransmitters/peptides on
different types of tumor growth.
Type of Innervation Tumor Type Neurotransmitters/Peptides/Activity
Inhibit (−)/Promote
(+) Tumor Growth
Extrinsic innervation Breast cancer [42] ↑ Sympatheticactivation +

































innervation? CRC [50] Substance P +
CRC [51,52] Neurotensin +
CRC [53] Somatostatin −
CRC [54,55] Galanin biomarker
CRC [58] Neuropeptide Y(NPY) +
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It is difficult to assess whether the contribution of neurons to colorectal carcinogenesis
is attributable to the extrinsic or intrinsic GI innervation. Even though some studies that
investigated the structural changes of the ENS in CRC have validated previous findings
that CRC is able to induce atrophy of the ENS [69,70], another study has demonstrated that
neuronal innervation in the tumor area increases in higher grade tumors [71]. Due to this
observation and the known prognostic value of PNI, different researchers studied the prog-
nostic value of other neuronal (related) markers in CRC. As described above, galanin has
been suggested as a possible biomarker for CRC in sera and tissue, and has been associated
with the recurrence of disease and lower survival rates in stage II CRC patients [72]. By per-
forming immunohistochemistry for tyrosine hydroxylase (TH) and vesicular acetylcholine
transferase (VAchT) on CRC tissue, Zhou et al. mainly detected sympathetic (TH+) fibers
in early phases of CRC, indicating good prognosis, while parasympathetic (VAchT+) inner-
vation was observed in later stages and indicated poor prognoses [73]. It should be noted
that a vast number of enteric neurons is cholinergic, and thus expresses VAchT [12], raising
the possibility that the observed nerve fibers are also of intrinsic origin. Acetylcholine
receptors are expressed in CRC tissue in a subpopulation of patients and their expression is
associated with a more advanced tumor stage, suggesting that cholinergic parasympathetic
nerves could signal to CRC tissue and aggravate disease. Of note, acetylcholine is not
necessarily produced only by neurons, but can also be released by colon cancer cells in an
autocrine fashion [74], indicating that caution has to be taken when drawing conclusions
regarding such neuron–cancer crosstalk observations. In contrast to neural input from the
ENS or the extrinsic innervation in CRC, the possibility that cancer cells trans-differentiate
into neural(-like) cells has been suggested as well [75]. Cancer stem cells isolated from
CRC patients are able to generate neurons in vitro, including sympathetic (TH+) neurons
positive for synaptic markers (SV2A and synapsin). Moreover, in prostate cancer, it has
been shown that doublecortin (DCX+) neural progenitors escape the blood–brain barrier
to infiltrate the tumor and generate new adrenergic neurons [76]. However, this process
has not yet been studied in CRC. It remains to be elucidated how intrinsic, extrinsic, and
cancer cell-derived neural input balances in colorectal carcinogenesis. Although the un-
derstanding of the role of nerves in cancer is increasing and there are strong indications
that nerves are indeed important in CRC, further research is necessary to gain mechanistic
insights in the crosstalk between nerves and cancer cells in the context of CRC.
3.2. Glia and Colorectal Cancer
The knowledge about the direct effects of EGCs on colorectal carcinogenesis is still
very limited. To study the relationship between CRC cells and EGCs, Valès et al. performed
in vitro experiments with those cells [77]. Co-culturing CRC stem cells (CSCs) with EGCs
(JUG–EGC cell line) increased the number and size of tumor spheres. The EGCs were
cultured on transwell filters and could not directly contact CRC cells, making it likely that
EGCs influenced the CSCs via paracrine signaling. Interestingly, the addition of media
of EGCs to CSC spheres was only able to increase tumor sphere numbers and size when
the EGCs were pre-incubated with CRC cell medium, indicating the importance of bi-
directional signaling. Furthermore, the study proposed a model where EGCs activated by
CRC medium increased PGE2 release which targeted CSCs and promoted tumor sphere
formation via activation of the EP4, EGFR and ERK1/2 pathways. In vivo experiments,
injecting human CRC cells with or without EGCs (JUG–EGC cell line) in mice, resulted in
increased tumor size in the presence of EGCs.
An in vivo study has confirmed the tumor-promoting role for EGCs in CRC devel-
opment [78]. GFAP+ EGCs were depleted in mouse models of CRC (AOM/DSS and
ApcMin/+) by injecting either ganciclovir in gfap-tk mice or diphtheria toxin in gfap-CRE
iDTR mice. Both EGC-depleted mice models showed reduced tumor burden, in num-
ber and size. However, once the cancerous lesions had formed, EGC depletion had no
effect on tumor burden, indicating that GFAP+ EGCs affect tumor development but not
tumor progression.
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Infiltration of EGCs in human CRC tumors was shown by staining for the glial markers
S100β and glial fibrillary acid protein (GFAP) [77]. Moreover, Seguella et al. investigated
the levels of S100β in colon biopsies of ten CRC patients and eight healthy subjects and
showed an increase in S100β expression compared to control, and subsequent activation of
the proliferation pathway RAGE/MAPK/NF-κB [79]. Moreover, upregulation of VEGF,
IL-6 and AQP4, markers for angiogenesis and invasion, correlated with S100β expression.
Based on GFAP immunohistochemistry, EGC density was observed to be the highest in
well-differentiated colorectal tumors, and decreased in moderately to poorly differentiated
colorectal tumors [80,81]. Furthermore, a high density of GFAP-positive EGCs correlated
with reduced proliferation of cancer cells (Ki-67 staining) and attenuated inflammation
(CD45 staining) in the tumor tissue [80]. Due to the contradictory findings of these studies,
future research will be necessary to explore the exact correlation between EGC density and
tumor development/progression. Furthermore, the molecules released by glia and the
substances/processes that activate and attract them need to be explored.
3.3. Other Members of the Tumor Microenvironment
It is important to realize that, even though neuronal cells and glial cells can influence
colorectal carcinogenesis directly, an interplay between these and other cells of the TME
will finally determine the fate of a tumor. Immune cells are the most studied members of
the tumor microenvironment in multiple cancers, and knowledge about their interaction
with extrinsic and intrinsic neurons and glia is rapidly developing [82–86]. In the gut,
muscularis macrophages have been shown to interact directly with enteric neurons and
EGCs [87–89]. How this interaction develops in the context of CRC is not yet known, but an
indirect effect of neurons and EGCs on CRC through immune cell regulation is one option.
Another link between the ENS and CRC could be the microbiome, which is known to be
involved in CRC [90] and interacts with both enteric neurons and EGCs [91,92]. Further
studies are needed to unravel the crosstalk between neurons, glia, and other cell types
to understand the role of the nervous system in CRC development and progression. In
addition, but not specific to CRC, Cole et al. described that the sympathetic nervous system
can regulate various processes involved in tumorigenesis, such as proliferation, angio-
genesis, and epithelial-mesenchymal transition [93]. In addition, Kuol et al. summarized
that various neurotransmitters released from nerve terminals, including serotonin and
glutamate, stimulate endothelial cells and the consequent angiogenic process, thereby
promoting tumor growth [94]. Lymphangiogenesis can be stimulated in a similar manner,
thereby conferring an aggressive advantage to the tumor [95]. Additionally, noradrenaline
signaling can, through the activation of β-adrenergic receptors, activate cancer-associated
fibroblasts (CAFs) which are able to remodel the extracellular matrix. This remodeling will
further support tumor growth [9,96–98] or lead to the collapse of blood vessels with a con-
comitant reduced penetration potential of therapeutics [99]. Thus, these data highlight the
importance of the different cell types of the TME for tumorigenesis and suggest that their
crosstalk with enteric neurons and EGCs can potentially affect the pathogenesis of CRC.
4. Therapeutic Potential
As described above, the presence of nerves and neuronal activity aggravate carcino-
genesis in most studies. Consequently, denervation of tumors has been postulated as a
therapeutic option for several cancers, including gastric [3] prostate [4] and breast can-
cer [6]. For CRC, denervation of the myenteric plexus using benzalkonium chloride (BAC)
reduced the number of aberrant crypt foci and other indicators of premalignant lesions,
suggesting that denervation of the colon in the early stages of CRC could attenuate carcino-
genesis [100]. Therapies which target PNI are described in different cancer types, which
mostly target NGF–TRKA signaling, because NGF is commonly overexpressed by cancer
cells [101]. Small molecule inhibitors of TRKA and antibodies targeting NGF have been
used in animal experiments and clinical trials to relieve cancer-associated pain, reverse
PNI, and inhibit cancer growth. It remains to be determined if similar strategies would be
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beneficial for the treatment of CRC as well. While PNI is targeted with radiation therapy
in head and neck cancer [102], PNI is not targeted specifically with radiotherapy in CRC.
Nonetheless, CRC tumors treated with neoadjuvant chemoradiation also had a decreased
occurrence of PNI [38], which seems to contribute to improved prognosis.
β-adrenergic receptors are also often described as potential therapeutic target for
different cancer types, and they are often present on cancer cells [103]. When activated by
sympathetic signaling, they can promote metastasis in several cancer types [103]. Whereas
β-adrenergic receptors are associated with tumor grade in CRC [71] and meta-analyses
of β-blocker use showed improved survival rates in patients with various types of cancer
(ovarian cancer, pancreatic cancer, and melanoma), no improved survival time was found
for CRC patients [104,105]. Further understanding about the role of the intrinsic and
extrinsic GI innervation in carcinogenesis is necessary before new therapeutic options
can be revealed, because the research on the role of the nervous system in CRC is still in
its infancy.
5. Conclusions and Future Directions
Nerves are increasingly recognized as an important member of the TME, participating
in carcinogenesis either (I) passively, serving as guiding strands for tumor spreading; or
(II) actively, by secreting trophic factors, neurotransmitters, and neuropeptides that can
influence cancer growth. This communication is bi-directional; cancer cells have been
shown to induce neuronal innervation and activation of the nervous system can worsen
disease outcomes. However, studies regarding the role of the nervous system in CRC
remain limited, even though the GI tract is highly innervated by both extrinsic and intrinsic
neural networks. Key questions that need to be addressed in future studies include: What
are the molecular mechanisms involved in the communication between neural cells and
CRC cells? Does neuron/glia–cancer crosstalk occur directly and/or through interplay
with other TME components? Which therapeutic options can be considered to intervene in
this crosstalk?
In several animal models of cancer, therapeutic denervation can lead to reduced
cancer growth, but it remains to be established whether this is also the case for human
subjects with CRC, and to what extent therapeutic denervation of the gut will be possible
while retaining all important bowel functions. Identifying to what extent the neural
contribution to colorectal carcinogenesis is of extrinsic and/or intrinsic origin imposes
another challenge, because these neural networks are extensively connected in the GI tract.
Patient stratification based on neural parameters might be valuable in the future for the
prognosis or prediction of treatment responses. All in all, more research is necessary to
elucidate the importance of the (enteric) nervous system in the pathogenesis of CRC, and
new insights could contribute to novel and more targeted treatment options.
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